Sign in

Economics of Genomics and Precision Medicine Unit

@eigen-uom.bsky.social
43 followers 21 following 35 posts

Generating health economics evidence to support cost-effective and value-based implementation of genomics and precision medicine. Melbourne Health Economics, The University of Melbourne

PostsRepliesMedia
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 23/02/2026
One of those weeks you don’t want to end! It was a pleasure to host our friends and collaborators from UBC. The visit provided a great opportunity to deepen our collaboration, exploring joint work in methodological development, cross-country analyses, and collaborative funding opportunities.
000
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 23/02/2026
Last week, the Economics of Genomics & Precision Medicine Unit hosted an Aus–Canada workshop on optimising genomic medicine, with 40 participants from academia, clinicians, Cancer Australia, Genomics Australia, PBAC/MSAC, industry, and consumer advocates. Excited to pursue ideas & collaborations!
000
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 18/02/2026
What is the value of genomic testing for Atrial Fibrillation? A new study led by Lizzy Liu and Ilias Goranitis found people highly value genomic testing for AF,at $2,900 for symptomatic patients and $2,600 for at risk relatives, with predicted uptake of 82% if publicly funded. go.unimelb.edu.au/xzr2
000
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 09/12/2025
We’re excited to welcome A/Prof Dean Regier as an Honorary within the EiGEN team. Dean is a leading international health economist at UBC and BC Cancer, with work spanning translational medicine, regulatory science, learning health systems and AI-supported real-world evidence in genomics.
000
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 27/11/2025
Determining the value of genomics in healthcare” is now published in Nature Medicine. Led by A/Prof Ilias Goranitis, the paper brings together international co-authors to examine how the value of genomics can be assessed. Read the full article: www.nature.com/articles/s41...
053
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 15/09/2025
000
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 15/09/2025
Lizzy Liu presented “Risk in preferences for breast cancer genomic risk screening and subsequent prevention protocols.”
100
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 15/09/2025
Last week, Lizzy Liu and Mackenzie Bourke presented in an organised session at the AHES Conference in Canberra on the value of population-wide genomic risk assessment for cancer screening, alongside A/Prof Julia Steinberg from the Daffodil Centre.
100
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 01/06/2025
Recently our team conducted two #DCEs as part of the BabyScreen+ program to elicit the Australian public’s preferences, values, and priorities for genomic newborn screening (gNBS) and its implementation. Read more here: sciencedirect.com/science/arti...
011
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 09/05/2025
Excited to welcome Thuy Dung (“Dzung”) Nguyen as our new Research Assistant in the Economics of Genomics and Precision Medicine Unit! Dzung will be contributing to a project evaluating the cost-effectiveness of genomic testing for children/adults with suspected kidney disease.
000
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 03/04/2025
This systematic review highlights where genomic medicine is likely cost-effective across the cancer care continuum, from: 🔹 Prevention & early detection 🔹 Diagnosis, staging & planning 🔹 Treatment 🔹 Managing refractory/relapsed disease 🔹 Palliative & end-of-life care
121
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 31/03/2025
Preferences like testing uptake, treatment adherence, and trust in the healthcare system are key to evaluating genomic medicine. Ignoring them can bias cost-effectiveness and policy relevance. 🔎 Read the paper our team supported: rdcu.be/eaJBy
000
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 28/03/2025
Using #MCDA, we elicited expert preference values for the diagnostic, clinical, family, economic, and societal components of genomic utility. This enabled the development of a scoring system ranging from 0% to 100%. The utility indicators used in the scale are shown in the table.
000
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 28/03/2025
Cancer Australia recently launched the National Framework for Genomics in Cancer Control, a major step toward integrating genomics into routine cancer care for all Australians. Read the Framework: canceraustralia.gov.au/key-initiati...
100
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 26/03/2025
Our recent micro-costing paper found that proteomics offers a more cost-effective solution with broader applications compared to respiratory chain enzymology for mitochondrial disorders in Australia. Read more of our findings here: ojrd.biomedcentral.com/articles/10....
Proteomics costs AU$897 (USD $607) per patient, outperforming traditional methods like respiratory chain enzymology in detecting mitochondrial and other rare diseases.
010